Happy Bob App Integrates With Dexcom CGM to Provide a Playful Way to Engage With Real-Time Glucose Values and Improve Overall Self-Care

Happy Bob App: Diabetes tech startup Harald AI today introduced a more expansive way for Dexcom Continuous Glucose Monitoring (CGM) System users to engage with their diabetes data through the popular Happy Bob App.

Through Dexcom’s real-time APIs, Happy Bob users can view their glucose values by quickly glancing at their Apple Watch or iPhone widget, create groups for support, collect stars and receive time-sensitive information and push notifications. Users can also see their historical data in the app for longer than 24 hours, access the expanded view, see insights on their desktop, and laugh at the in-app personalized messaging. Created by and for people with diabetes, Team Happy Bob has developed an app that alleviates the stress of daily management and glycemic control.

“Dexcom’s new Partner Web APIs opens the door for the future of connected devices. We are really excited to be one of their first collaborators and look forward to Dexcom users experiencing Happy Bob’s playful interface and ease of use. Diabetes exacts a huge mental toll and our app is designed to alleviate the data overload involved with daily care and glycemic control. Happy Bob is here to make your day better, and this partnership with Dexcom makes Happy Bob better able to do that,” says Jutta Haaramo, CEO at Harald AI.

Initially released in 2019, Happy Bob App quickly became popular with CGM users, who appreciated the personalized messages and gamification it offered. Embracing a lighter side to diabetes management was a game-changer in the digital data space and as a result, users were instantly more engaged and motivated to care for their health.

“Diabetes management is not a one-size-fits-all model, which is why we have always prioritized making our CGM data accessible to users in the platform of their choice,” said Jake Leach, executive vice president and chief technology officer at Dexcom. “We are excited to introduce Happy Bob as the latest partner to leverage our real-time APIs, which helps enable a more personalized and connected approach to continuous glucose monitoring.”

The Happy Bob App is available for download from the Apple App Store and Google Play Store for Dexcom CGM users in the U.S.

SourceHarald AI

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version